POLYMYXIN B SULFATE (polymyxin b sulfate) by Fresenius Kabi is clinical pharmacology polymyxin b sulfate has a bactericidal action against almost all gram-negative bacilli except the proteus group. Approved for serious infections caused by susceptible strains of the following organisms, less potentially toxic drugs are ineffective, contraindicated: h influenzae and 1 more indications. First approved in 2008.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of the bacterial cell membrane leading to death of the cell. All gram-positive bacteria, fungi, and gram-negative cocci are…
Worked on POLYMYXIN B SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.